Dasatinib in Combination With Revlimid (and Dexamethasone)
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety and tolerability of dasatinib when
given in combination with lenalidomide and a low dose dexamethasone for the treatment of
relapsed or refractory multiple myeloma.